Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?

被引：0
|
作者：
Vitale, Pasquale [1 ]
De Falco, Vincenzo [1 ]
Addeo, Raffaele [1 ,2 ]
机构：
[1] Hosp Frattamaggiore, Oncol Operat Unit, Frattamaggiore, Italy
[2] ASLNA2NORD, San Giovanni Dio Hosp, Oncol Operat Unit, Via D Pirozzi 62, I-80027 Frattamaggiore, NA, Italy
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2024年 / 24卷 / 07期
关键词：
Recurrent/metastatic head and neck cancer; cetuximab; PD-L1; pembrolizumab; chemotherapy; combined positive score; SQUAMOUS-CELL CARCINOMA; CHEMOTHERAPY PLUS CETUXIMAB; RECURRENT; PEMBROLIZUMAB; KEYNOTE-048;
D O I：
10.1080/14737140.2024.2354772
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：481 / 484
页数：4
相关论文
共 50 条
  • [31] Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial
    Rivera, Fernando
    Garcia-Castano, Almudena
    Vega, Noelia
    Eugenia Vega-Villegas, M.
    Gutierrez-Sanz, Lourdes
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (10) : 1421 - 1428
  • [32] First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (12) : 2134 - +
  • [33] First-line treatment in metastatic colorectal cancer: Important or crucial?
    Malka, David
    Rotolo, Federico
    Boige, Valerie
    EUROPEAN JOURNAL OF CANCER, 2017, 84 : 363 - 366
  • [34] Cetuximab since 10 Years in the First-line Standard for Patients with Head and Neck Cancer
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (06) : 407 - 407
  • [35] First line cetuximab and cisplatin with or without paclitaxel in recurrent/metastatic head and neck cancer: A randomized phase IIb trial
    Bossi, P.
    Hollander, L. H.
    Miceli, R.
    Ferrari, D.
    Vecchio, S.
    Moretti, G.
    Merlano, M.
    Caponigro, F.
    Moro, C.
    Vaccher, E.
    Alabisio, O.
    Caldara, A.
    Russo, A.
    Ferrau, F.
    Nole, F.
    Licitra, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
    Colevas, D. A.
    Misiukiewicz, K.
    Pearson, A. T.
    Fayette, J.
    Bauman, J. R.
    Cupissol, D.
    Saada-Bouzid, E.
    Adkins, D. R.
    Marie, D. B.
    Cornen, S. L.
    Andre, P.
    Carrette, F.
    Rotolo, F.
    Boyer Chammard, A.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1432 - S1432
  • [37] Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
    Guigay, J.
    Fayette, J.
    Dillies, A. F.
    Sire, C.
    Kerger, J. N.
    Tennevet, I.
    Machiels, J. P.
    Zanetta, S.
    Pointreau, Y.
    Bozec Le Moal, L.
    Henry, S.
    Schilf, A.
    Bourhis, J.
    ANNALS OF ONCOLOGY, 2015, 26 (09) : 1941 - 1947
  • [38] Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy
    Siano, Marco
    Infante, Gabriele
    Resteghini, Carlo
    Cau, Maria Chiara
    Alfieri, Salvatore
    Bergamini, Cristiana
    Granata, Roberta
    Miceli, Rosalba
    Locati, Laura
    Licitra, Lisa
    Bossi, Paolo
    ORAL ONCOLOGY, 2017, 69 : 33 - 37
  • [39] Persistent Head and Neck Cancer Following First-Line Treatment
    Steinbichler, Teresa Bernadette
    Lichtenecker, Madeleine
    Anegg, Maria
    Dejaco, Daniel
    Kofler, Barbara
    Schartinger, Volker Hans
    Kasseroler, Maria-Therese
    Forthuber, Britta
    Posch, Andrea
    Riechelmann, Herbert
    CANCERS, 2018, 10 (11):
  • [40] Pembrolizumab in the first-line treatment of advanced head and neck cancer
    de Sousa, Luana Guimaraes
    Ferrarotto, Renata
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1321 - 1331
12345